Literature DB >> 18506921

In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis.

Andreas Weber1, Wolfgang Huber, Klaus Kamereck, Philipp Winkle, Petra Voland, Hans Weidenbach, Roland M Schmid, Christian Prinz.   

Abstract

AIM: To analyze the in vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens isolated from patients with acute cholangitis.
METHODS: In this prospective study a total of 65 patients with acute cholangitis due to biliary stone obstruction (n = 7), benign biliary stricture (n = 16), and malignant biliary stricture (n = 42) were investigated with regard to spectrum of bacterial infection and antibiotic resistance. Pathogens were isolated from bile cultures in all study patients. In 22 febrile patients, blood cultures were also obtained. In vitro activity of moxifloxacin and piperacillin/sulbactam was determined by agar diffusion.
RESULTS: Thirty-one out of 65 patients had positive bile and/or blood cultures. In 31 patients, 63 isolates with 17 different species were identified. The predominant strains were Enterococcus species (26/63), E.coli (13/63) and Klebsiella species (8/63). A comparable in vitro activity of moxifloxacin and piperacillin/sulbactam was observed for E.coli and Klebsiella species. In contrast, Enterococcus species had higher resistances towards moxifloxacin. Overall bacteria showed antibiotic resistances in vitro of 34.9% for piperacillin/sulbactam and 36.5% for moxifloxacin.
CONCLUSION: Enterococcus species, E.coli and Klebsiella species were the most common bacteria isolated from bile and/or blood from patients with acute cholangitis. Overall, a mixed infection with several species was observed, and bacteria showed a comparable in vitro activity for piperacillin/sulbactam and moxifloxacin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18506921      PMCID: PMC2712848          DOI: 10.3748/wjg.14.3174

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

1.  [Interventional ERCP in patients with cholestasis. Degree of biliary bacterial colonization and antibiotic resistance].

Authors:  R Kiesslich; M Holfelder; D Will; M Hahn; B Nafe; R Genitsariotis; S Daniello; M Maeurer; M Jung
Journal:  Z Gastroenterol       Date:  2001-12       Impact factor: 2.000

2.  Microbiological examinations and in-vitro testing of different antibiotics in therapeutic endoscopy of the biliary system.

Authors:  R Lorenz; M Herrmann; A M Kassem; N Lehn; H Neuhaus; M Classen
Journal:  Endoscopy       Date:  1998-10       Impact factor: 10.093

3.  Aerobic and anaerobic microbiology of biliary tract disease.

Authors:  I Brook
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

4.  The bacteriology of the obstructed biliary tree.

Authors:  A C Maddocks; G R Hilson; R Taylor
Journal:  Ann R Coll Surg Engl       Date:  1973-05       Impact factor: 1.891

5.  Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract.

Authors:  S J van den Hazel; X H de Vries; P Speelman; J Dankert; G N Tytgat; K Huibregtse; D J van Leeuwen
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  Microbiology of choledochal bile in patients with choledocholithiasis admitted to a tertiary hospital.

Authors:  Cristina Flores; Ismael Maguilnik; Everton Hadlich; Luciano Z Goldani
Journal:  J Gastroenterol Hepatol       Date:  2003-03       Impact factor: 4.029

7.  Antimicrobial therapy for acute cholangitis: Tokyo Guidelines.

Authors:  Atsushi Tanaka; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Masahiro Yoshida; Fumihiko Miura; Masahiko Hirota; Keita Wada; Toshihiko Mayumi; Harumi Gomi; Joseph S Solomkin; Steven M Strasberg; Henry A Pitt; Jacques Belghiti; Eduardo de Santibanes; Robert Padbury; Miin-Fu Chen; Giulio Belli; Chen-Guo Ker; Serafin C Hilvano; Sheung-Tat Fan; Kui-Hin Liau
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-01-30

8.  Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum.

Authors:  M R Keighley; R B Drysdale; A H Quoraishi; D W Burdon; J Alexander-Willians
Journal:  Gut       Date:  1976-07       Impact factor: 23.059

9.  Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis.

Authors:  Rungsun Rerknimitr; Evan L Fogel; Cem Kalayci; Edward Esber; Glen A Lehman; Stuart Sherman
Journal:  Gastrointest Endosc       Date:  2002-12       Impact factor: 9.427

10.  Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group.

Authors:  S Chamberland; J L'Ecuyer; C Lessard; M Bernier; P Provencher; M G Bergeron
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

View more
  3 in total

1.  Treatment of chronic proliferative cholangitis with c-myc shRNA.

Authors:  Fu-Yu Li; Nan-Sheng Cheng; Jing-Qiu Cheng; Hui Mao; Li-Sheng Jiang; Ning Li; Sheng He
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

Review 2.  Cholangitis: Diagnosis, Treatment and Prognosis.

Authors:  Amir Houshang Mohammad Alizadeh
Journal:  J Clin Transl Hepatol       Date:  2017-09-07

3.  Clinical and microbiological characteristics of patients with biliary disease.

Authors:  Xue-Xiang Gu; Meng-Pei Zhang; Yan-Feng Zhao; Guang-Ming Huang
Journal:  World J Gastroenterol       Date:  2020-04-14       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.